Moderna vs Morgan Stanley

Moderna Market Stance

Moderna's story is one of the most extraordinary in the history of biotechnology — a company that spent a decade building technology that most of the scientific establishment considered theoretically interesting but practically unproven, and then, in the space of eleven months, deployed that technology to produce one of the most effective vaccines in history and transform global public health. The COVID-19 pandemic did not create Moderna's scientific capability; it revealed it to the world. Founded in 2010 by Noubar Afeyan, Robert Langer, and Derrick Rossi — with Stéphane Bancel recruited as CEO in 2011 — Moderna was built around a single foundational insight: messenger RNA, the molecule that carries genetic instructions from DNA to the cell's protein-making machinery, could be engineered and delivered as a therapeutic. If you could instruct a patient's own cells to produce a specific protein — an antigen that triggers immune response, an enzyme that replaces a missing one, a receptor that enables cellular signaling — you could potentially treat or prevent diseases that conventional small-molecule drugs and protein biologics could not address. The scientific challenges this vision confronted were formidable. Natural mRNA is inherently unstable and degrades quickly in the body. The immune system is designed to recognize and destroy foreign RNA as a pathogen — meaning delivered mRNA would trigger inflammatory responses before it could do its intended work. And delivering mRNA to the right cells in the right concentration required delivery vehicles that did not exist in commercially viable forms in 2010. Moderna's first decade was devoted to solving these problems, largely out of public view. The company raised extraordinary amounts of private capital — over USD 2 billion before its 2018 IPO — to fund the basic research and clinical development required to make mRNA therapeutics work. It developed proprietary modifications to mRNA's chemical structure that reduced immunogenicity (the tendency to trigger immune reactions) while maintaining translational efficiency (the ability to instruct protein production). It developed lipid nanoparticle (LNP) delivery systems — tiny fat bubbles that could carry mRNA into cells without triggering immune destruction. And it built the manufacturing infrastructure required to produce mRNA at pharmaceutical scale with the quality consistency that regulatory approval demands. The company went public in December 2018 at a USD 7.5 billion valuation — the largest biotech IPO in history at that time — despite having no approved products and revenue consisting almost entirely of government grants and collaboration payments. The IPO reflected investor conviction that Moderna's platform had genuine potential, not just in vaccines but across the full spectrum of therapeutic applications that programmable protein production could address. When SARS-CoV-2 emerged in early 2020, Moderna had already been developing mRNA vaccine candidates for other respiratory viruses including MERS and influenza. The company began designing its COVID-19 vaccine candidate — mRNA-1273 — within days of the viral sequence becoming publicly available in January 2020, and commenced Phase 1 clinical trials in March 2020, approximately 66 days after the sequence release. This speed — impossible with conventional vaccine development timelines that typically require years of antigen selection, production scale-up, and preclinical work — was the direct consequence of a decade of platform investment. The Phase 3 trial of mRNA-1273 demonstrated 94.1% efficacy against symptomatic COVID-19, and the vaccine received Emergency Use Authorization from the FDA in December 2020. The commercial rollout was unlike anything in Moderna's history — or, arguably, in the history of any biotechnology company. The U.S. government had pre-purchased hundreds of millions of doses; governments worldwide competed for supply; and Moderna's manufacturing infrastructure, built with government partnership funding, produced billions of doses in 2021 and 2022. The financial consequences were transformative. Moderna's revenue went from USD 803 million in 2020 (primarily from BARDA and other government contracts) to USD 17.7 billion in 2021 and USD 19.3 billion in 2022 — generating cumulative net income in 2021–2022 of approximately USD 22 billion. A company that had never been profitable in its first decade became, briefly, one of the most profitable pharmaceutical companies on earth. The post-pandemic transition — from single-product COVID-19 revenue to a diversified mRNA therapeutic portfolio — is the defining strategic challenge of Moderna's current existence. The COVID-19 vaccine market has contracted sharply as global vaccination rates matured and annual booster demand settled at levels far below peak. Moderna's 2023 revenue fell to USD 6.8 billion and 2024 revenue declined further to approximately USD 3.2 billion — a revenue contraction that would be catastrophic for most companies but that Moderna had partially anticipated and for which it had accumulated substantial cash reserves during the peak years.